Table 1. Clinicopathological features of the 168 patients with combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 WHO classification.

Values are presented as number (%), mean ± standard deviation, or number only if otherwise specified.

PIVKA-II, proteins induced by vitamin K antagonist or absence-II; ICG-R15, indocyanine green retention test at 15 minutes; MELD, model for end-stage liver disease; AJCC, American Joint Committee on Cancer.

^a)A vs. (B + C + D + E). ^b)Viral hepatitis vs. others. ^c)Stage I vs. other advanced stages.